JW Pharm to discuss technical partnerships for its gout Tx

Will participate in the 2022 JP Morgan Healthcare Conference

JW Pharmaceutical will be discussing technical partnerships for its key new drug candidates such as URC102 and JW2286 with global pharmaceutical companies.

 

On the 20th, JW Pharmaceutical announced that it will be attending the ‘2022 JP Morgan Healthcare Conference’ that will be held online from the 10th next month (local time) and introduce its research projects to overseas pharmaceutical companies and global investors and conduct one-on-one virtual partnership consultations.

 

The company plans to discuss tech partnerships for its self-developed innovative drug candidates at the conference.

 

For example, the company will be promoting the technology export of its gout treatment URC102 to the global market, other than China.

 

JW Pharmaceutical had signed a technology transfer agreement for URC102 with a Chinese company, Simcere Pharmaceutical, in 2019.

 

The safety and efficacy of URC102 were demonstrated through a Phase 2b clinical trial that was completed in March.

 

The company had also started a clinical trial to extend the eligibility of the drug to patients with nephropathies.

 

A Phase III trial on these subjects is expected to start next year.

 

Also, the company will promote technology partnerships for its STAT3-targeted anticancer drug, JW2286.

 

JW2286 inhibits STAT3 and is indicated for the treatment of solid tumors, such as triple-negative breast cancer, gastric cancer, colorectal cancer, etc.

 

The company is conducting nonclinical studies and drug manufacturing research to initiate clinical trials.

 

STAT3 is a protein that promotes the expression of multiple genes.

 

The abnormal activation of STAT3 causes tumor cell growth, proliferation, metastasis, and drug tolerance, but none had succeeded in developing anticancer drugs targeting STAT3 so far.

 

Also, JW Pharmaceuticals will share its latest research and clinical development strategies on JW0061, a new drug candidate for hair loss that differentiates and promotes hair follicle stem cells involved in hair formation by activating the Wnt signaling pathway that regulates cell proliferation and regeneration, and JW1601, a drug that is extending its indication to age-related macular degeneration and ophthalmologic diseases such as allergic conjunctivitis, etc..

 

Around 1,500 pharmaceutical and bio companies from 50 countries attend the JP Morgan Healthcare Conference every year.

 

Companies attend the conference to introduce their pipelines and technology to global healthcare companies.

 

Also, participating companies are provided with an opportunity to meet with funds like venture capitals, hedge funds, PFEs, etc.